These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25163019)

  • 1. A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection.
    Burton MJ; Penman A; Sunesara I; McGuire BM; Hook EW
    Am J Med Sci; 2014 Dec; 348(6):455-9. PubMed ID: 25163019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
    Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
    Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
    Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
    Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
    JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
    Tyring SK; Baker D; Snowden W
    J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
    J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
    Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
    Handsfield HH; Warren T; Werner M; Phillips JA
    Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
    Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
    J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.
    Baker D; Eisen D
    Cutis; 2003 Mar; 71(3):239-42. PubMed ID: 12661753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
    Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
    J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
    Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
    J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
    Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
    Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
    Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
    Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.